GT Biopharma GTBP
NASDAQ GTBP
$5.43 +0.02 (+0.38%)
As of: Oct 22, 2026 · 11:25 AM EDT

GT Biopharma (GTBP) Long-Term Debt Repayments (2011 - 2019)

Updated

GT Biopharma (GTBP) reported Long-Term Debt Repayments of $100,000 for FY2019, down 97.7% from $4.42 million in FY2018.

Analysis

GT Biopharma (GTBP) Long-Term Debt Repayments (2011 - 2019) Analysis & Trends

Dating back to FY2013, GT Biopharma's Long-Term Debt Repayments record includes 4 years.

  • Long-Term Debt Repayments has a five-year compound annual growth rate of 75.5% (FY2014 to FY2019).
  • The FY2019 figure ranks as the lowest annual Long-Term Debt Repayments since FY2014.
  • According to Business Quant data, Long-Term Debt Repayments came in at $4.42 million in FY2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,172.00 Bn 1,140.58 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 639.12 Bn 557.64 Bn 17.26 Bn 1.00 Mn
3 AbbVie 502.23 Bn 475.34 Bn 12.70 Bn 2.00 Bn
4 Merck 375.29 Bn 329.67 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 302.99 Bn 266.98 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 268.68 Bn 242.36 Bn 12.86 Bn 2.46 Bn
7 Amgen 242.24 Bn 197.64 Bn 7.24 Bn -
8 Gilead Sciences 193.36 Bn 167.56 Bn 6.22 Bn 17.00 Mn
9 Pfizer 172.57 Bn 119.21 Bn 10.94 Bn -
10 GT Biopharma 6.58 Mn -16.91 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 100,000.00
Dec 31, 2018 -4,000.00
Sep 30, 2018 4.42 Mn
Dec 31, 2014 6,000.00
Dec 31, 2013 -26,000.00
Mar 31, 2013 34,000.00
Dec 31, 2011 -50,000.00
API Access

GT Biopharma Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=GTBP&period=max&api_key=YOUR_API_KEY